Chembio Diagnostics Announces Retirement of Chief Financial Officer
August 17 2017 - 5:00PM
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in
point-of-care (POC) diagnostic tests for infectious
diseases, today announced that Richard J. Larkin,
Executive Vice President and Chief Financial Officer (CFO), has
informed the Company of his intention to retire by December 31,
2017.
An external search for a new Company CFO will
commence immediately. To ensure an orderly transition, Mr. Larkin
is expected to continue to serve as the Company’s CFO and remain an
officer of the Company until the earlier of December 31, 2017 or
until a successor is found.
Sharon Klugewicz, acting Chief Executive
Officer, commented, “On behalf of the Board of Directors, I would
like to thank Rich for his dedication and commitment to the Company
over the last fourteen years. He has been a valuable member of our
executive leadership team and we wish him well as he transitions
into retirement.”
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops,
manufactures, licenses and markets rapid diagnostic tests in the
growing $8.0 billion POC testing market. The Company markets its
products directly and through third-party distributors under
the brand names: DPP®, STAT-PAK® and SURE CHECK®
Chembio has developed and patented
the DPP® technology platform, which offers significant
advantages over traditional POC lateral-flow technologies and
provides the Company with a significant pipeline of business
opportunities in the area of sexually transmitted disease, tropical
and fever disease, and technology collaborations.
Headquartered in Medford, NY, Chembio is
licensed by the U.S. Food and Drug Administration (FDA) as well as
the U.S. Department of Agriculture (USDA), and is certified for the
global market under the International Standards Organization (ISO)
directive 13485. Each of Chembio Diagnostic Systems, Inc. and RVR
Diagnostics Sdn Bhd is a wholly-owned subsidiary of Chembio
Diagnostics, Inc. For more information, please
visit: www.chembio.com.
Forward-Looking Statements
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act
of 1933, as amended. Forward-looking statements include
statements regarding the intent, belief or current expectations of
the Company and its management. Such statements, which are
estimates only, reflect management's current views, are based on
certain assumptions, and involve risks and uncertainties.
Actual results, events, or performance may differ materially from
the above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors,
including, but not limited to Chembio's ability to
obtain additional financing and to obtain regulatory approvals
in a timely manner, as well as the demand for Chembio's
products. Chembio undertakes no obligation to publicly update
these forward-looking statements to reflect events or circumstances
that occur after the date hereof or to reflect any change in
Chembio's expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in
Chembio's most recent public filings with the U.S. Securities and
Exchange Commission.
Contacts:
Vida Strategic Partners (investor relations)
Stephanie C. Diaz
(415) 675-7401
sdiaz@vidasp.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024